GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Debt-to-Equity

EVOK (Evoke Pharma) Debt-to-Equity : 0.73 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Evoke Pharma Debt-to-Equity?

Evoke Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $5.06 Mil. Evoke Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.10 Mil. Evoke Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $7.04 Mil. Evoke Pharma's debt to equity for the quarter that ended in Dec. 2024 was 0.73.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Evoke Pharma's Debt-to-Equity or its related term are showing as below:

EVOK' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.94   Med: 0.73   Max: 1.41
Current: 0.73

During the past 13 years, the highest Debt-to-Equity Ratio of Evoke Pharma was 1.41. The lowest was -1.94. And the median was 0.73.

EVOK's Debt-to-Equity is ranked worse than
78.8% of 816 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs EVOK: 0.73

Evoke Pharma Debt-to-Equity Historical Data

The historical data trend for Evoke Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Debt-to-Equity Chart

Evoke Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.63 1.41 1.26 -1.94 0.73

Evoke Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.94 1.43 1.88 1.14 0.73

Competitive Comparison of Evoke Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Debt-to-Equity falls into.


;
;

Evoke Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Evoke Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Evoke Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evoke Pharma  (NAS:EVOK) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Evoke Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma Business Description

Traded in Other Exchanges
N/A
Address
420 Stevens Avenue, Suite 230, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Executives
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer director, officer: President and CEO C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio officer: Exec VP, Chief Bus. Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder director, 10 percent owner 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah 10 percent owner 12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson officer: Chief Medical Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady director C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn director
Lvpmc, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p. 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111